1711 Results
Sort By:
Published on April 25, 2024
In a bold move to strategically grow its specialty pharmacy services, Walgreens will offer gene and cell therapies. The company yesterday introduced Walgreens Specialty Pharmacy, a move it says will expand access to care for patients with complex, chronic conditions, and will grow the company’s business. This includes a new…
Published on April 24, 2024
A Phase I trial led by the Baylor College of Medicine shows an autologous chimeric antigen receptor (CAR) T-cell therapy for treatment of advanced HER2-specific sarcoma was beneficial in 50% of patients in the trial. Lower-level cytokine release syndrome was fairly common in the study, but only two individuals had…
Published on April 3, 2024
Adaptimmune’s pivotal SPEARHEAD-1 trial has shown that the T cell receptor therapy afami-cel effectively targets metastatic synovial sarcoma and myxoid round cell liposarcoma, potentially opening the door for other solid tumors to be treated with T cell therapies. “Synovial sarcoma is a rare cancer with historically limited treatment options and…
Published on March 19, 2024
A team of French researchers has found that the use of magnetic resonance imaging (MRI) and lumbar puncture (LP) may not always be necessary as a diagnostic tool to help doctors manage serious neurotoxicity related to CAR T-cell therapy. The study, published today in the journal Blood Advances, further validated…
Published on March 13, 2024
Researchers at City of Hope report the first-ever chimeric antigen receptor (CAR) T-cell treatment of recurrent brain tumors delivered directly to the tumor, bypassing the protective blood-brain barrier. The study marks the completion of the largest Phase I clinical trial to date for any solid tumor type. “We’re going after…
Published on February 27, 2024
Researchers at the University of Pennsylvania report a variant of the p53 protein may improve the effectiveness of chimeric antigen receptor (CAR) T cell therapy. The findings are published in The Proceedings of the National Academy of Sciences and led by Carl June, MD, the Richard W. Vague Professor in…
Published on February 21, 2024
The Food and Drug Administration (FDA) has granted accelerated approval to lifileucel (Amtagvi, Iovance Biotherapeutics), a tumor-derived autologous T cell immunotherapy, for adult patients with unresectable or metastatic melanoma. It is the first, and the only one-time, T cell therapy to receive FDA approval for a solid tumor cancer. The…
Published on February 6, 2024
A new study, led by Australian researchers at Monash University, demonstrates a method to reprogram defective cells that could lead to a new cell therapy to provide an effective long-term treatment for lupus. Using human cells from healthy people, the research team developed a treatment that restores the protective aspects…
Published on February 6, 2024
Results from a Phase I/II study show a cell therapy developed by MiNK Therapeutics could be an effective treatment for patients with acute respiratory distress syndrome (ARDS) after COVID-19 or flu infection. Although the research was early stage, the results showed that the survival rate of the patients given the…
Published on January 19, 2024
In a crucial Phase I/II trial, researchers at The University of Texas MD Anderson Cancer Center have reported significant success in treating patients with relapsed or refractory B-cell malignancies using cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19. The findings, published in Nature Medicine, show…
Published on December 18, 2023
Immusoft has dosed the first patient with an engineered B cell therapy—ISP-001 for MPS I (Mucopolysaccharidosis type I). This approach has several potential advantages over current gene and cell therapies. It does not require preconditioning (myeloablative chemotherapy) or immunosuppression, is administered as an IV on an outpatient basis, and it…
Published on December 11, 2023
A chimeric antigen receptor (CAR) T-cell therapy with a new cellular binding mechanism targeting CD19 has achieved good results in a Phase I trial in patients with relapsed or refractory B cell non-Hodgkin’s lymphoma. As reported in the journal Molecular Cancer, the new therapy had an overall response rate of…
Published on November 6, 2023
Researchers at the German Center for Neurodegenerative Diseases (DZNE) and the Charité University Hospital in Berlin, Germany, have engineered a new type of specialized T cell that can be used to treat autoimmune encephalitis. Autoimmune encephalitis is a condition in which the body’s own antibodies cross the blood-brain barrier and…
Published on September 12, 2023
Research from Tongji University in Shanghai shows promising results from a Phase I human study of a cell therapy to treat chronic obstructive pulmonary disease (COPD). A group of 17 patients had notable improvements in breathing, walking distance, and quality of life after receiving the therapy, which is created using…
Published on August 16, 2023
A team of investigators at City of Hope, one of the largest cancer research and treatment organizations in the US, report in Nature Communications that they have engineered a CAR T cell therapy for advanced ovarian cancer that has shown promise in laboratory and preclinical models. Based on the preclinical…